Literature DB >> 25891057

Trends in exposure to televised prescription drug advertising, 2003-2011.

Rachel Kornfield1, G Caleb Alexander2, Dima M Qato3, Yoonsang Kim4, Jan D Hirsch5, Sherry L Emery4.   

Abstract

INTRODUCTION: TV accounts for more than half of pharmaceutical direct-to-consumer advertising (DTCA) spending in the U.S. The purpose of this study is to quantify average household exposure to branded and non-branded (help-seeking) televised prescription drug advertisements and describe variation over time and according to medication indication and geography.
METHODS: In 2013, Nielsen TV ratings were compiled for prescription pharmaceutical advertising that aired between 2003 and 2011 for the top 75 U.S. media markets. All advertisements were coded as branded or help-seeking. Advertisements were further coded for one of eight prevalent indications (allergies, arthritis, asthma, erectile dysfunction, high cholesterol, smoking cessation, depression, and sleep disorder) or as "other."
RESULTS: Televised DTCA exposure increased from 2003 to 2007 and then declined 43% by 2011, to 111 monthly prescription drug advertisements per household. The examined indications were associated with varying amounts and patterns of exposure, with greatest declines among medications for allergies and sleep disorders. Help-seeking advertisements comprised 10% of total exposure, with substantial variation by indication.
CONCLUSIONS: Considerations of DTCA's effects on health care should take into account the shifting concentration of advertising across indications.
Copyright © 2015 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25891057      PMCID: PMC4405658          DOI: 10.1016/j.amepre.2014.12.001

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  21 in total

1.  Selling sickness: the pharmaceutical industry and disease mongering.

Authors:  Ray Moynihan; Iona Heath; David Henry
Journal:  BMJ       Date:  2002-04-13

2.  Direct-to-consumer drug advertisements on network television: an exploration of quantity, frequency, and placement.

Authors:  Erica D Brownfield; Jay M Bernhardt; Jennifer L Phan; Mark V Williams; Ruth M Parker
Journal:  J Health Commun       Date:  2004 Nov-Dec

3.  A content analysis of direct-to-consumer television prescription drug advertisements.

Authors:  Kimberly A Kaphingst; William DeJong; Rima E Rudd; Lawren H Daltroy
Journal:  J Health Commun       Date:  2004 Nov-Dec

4.  Effects of pharmaceutical promotion on adherence to the treatment guidelines for depression.

Authors:  Julie M Donohue; Ernst R Berndt; Meredith Rosenthal; Arnold M Epstein; Richard G Frank
Journal:  Med Care       Date:  2004-12       Impact factor: 2.983

5.  Direct-to-consumer advertising: a haphazard approach to health promotion.

Authors:  Matthew F Hollon
Journal:  JAMA       Date:  2005-04-27       Impact factor: 56.272

Review 6.  Methodological challenges surrounding direct-to-consumer advertising research--the measurement conundrum.

Authors:  Richard A Hansen; Marcus Droege
Journal:  Res Social Adm Pharm       Date:  2005-06

Review 7.  Direct-to-consumer advertising of pharmaceuticals.

Authors:  Ziad F Gellad; Kenneth W Lyles
Journal:  Am J Med       Date:  2007-06       Impact factor: 4.965

8.  Generic entry, reformulations and promotion of SSRIs in the US.

Authors:  Haiden A Huskamp; Julie M Donohue; Catherine Koss; Ernst R Berndt; Richard G Frank
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

9.  The politics and strategy of industry self-regulation: the pharmaceutical industry's principles for ethical direct-to-consumer advertising as a deceptive blocking strategy.

Authors:  Denis G Arnold; James L Oakley
Journal:  J Health Polit Policy Law       Date:  2013-02-15       Impact factor: 2.265

10.  Promotion of prescription drugs to consumers and providers, 2001-2010.

Authors:  Rachel Kornfield; Julie Donohue; Ernst R Berndt; G Caleb Alexander
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

View more
  8 in total

Review 1.  A framework for evaluating the public health impact of e-cigarettes and other vaporized nicotine products.

Authors:  David T Levy; K Michael Cummings; Andrea C Villanti; Ray Niaura; David B Abrams; Geoffrey T Fong; Ron Borland
Journal:  Addiction       Date:  2016-04-25       Impact factor: 6.526

2.  Key Features of Academic Detailing: Development of an Expert Consensus Using the Delphi Method.

Authors:  James S Yeh; Thomas J Van Hoof; Michael A Fischer
Journal:  Am Health Drug Benefits       Date:  2016-02

3.  Communicating Risk Information in Direct-to-Consumer Prescription Drug Television Ads: A Content Analysis.

Authors:  Helen W Sullivan; Kathryn J Aikin; Jon Poehlman
Journal:  Health Commun       Date:  2017-11-10

4.  The (Surprising) Impact of Televised Antidepressant Direct-to-Consumer Advertising on the Stigmatization of Mental Illness.

Authors:  Nicolette Rainone; Reshma Oodal; Jeff Niederdeppe
Journal:  Community Ment Health J       Date:  2017-09-08

5.  Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013.

Authors:  J Bradley Layton; Yoonsang Kim; G Caleb Alexander; Sherry L Emery
Journal:  JAMA       Date:  2017-03-21       Impact factor: 56.272

6.  Mixed Messages, Mixed Outcomes: Exposure to Direct-to-Consumer Advertising for Statin Drugs is Associated with More Frequent Visits to Fast Food Restaurants and Exercise.

Authors:  Jeff Niederdeppe; Rosemary J Avery; Maxwell D Kellogg; Alan Mathios
Journal:  Health Commun       Date:  2016-07-18

7.  The Effect of Including Quantitative Information on Multiple Endpoints in Direct-to-Consumer Prescription Drug Television Advertisements.

Authors:  Helen W Sullivan; Amie C O'Donoghue; Molly Lynch; Mihaela Johnson; Christine Davis; Douglas J Rupert
Journal:  Med Decis Making       Date:  2019-10-04       Impact factor: 2.583

8.  Prescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug Administration.

Authors:  Helen W Sullivan; Kathryn J Aikin; Eunice Chung-Davies; Michael Wade
Journal:  PLoS One       Date:  2016-05-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.